How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,868 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults

on this time course. Coinfected individuals progress more rapidly to liver fibrosis, cirrhosis and ESLD compared with those infected with HCV alone (47-50). In a meta-analysis, the RR for cirrhosis was 2.49 (95% CI 1.81 to 3.42) in ART -untreated and 1.72 (95% CI 1.06 to 2.80) in ART - treated coinfected versus monoinfected individuals (50). Once cirrhosis develops, there is also a dramatic sixfold acceleration to decompensation and death (47). Fibrosis rates in HIV-infected MSM acquiring acute HCV while (...) on ART have also been shown to be surprisingly rapid, sug- gesting an accelerated course of HCV despite effective HIV control (51). This more rapid course is driving, in large measure, the increased liver-related mortality that has been observed worldwide in developed countries in the post-ART era. In a large HIV cohort collaboration (the Data Collection o n Adverse events of Anti-HIV Drugs [D:A:D] study), liver-related deaths (14% overall) were second only to AIDS and were associated

2014 CPG Infobase

42. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV

Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV UPDATED RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION DECEMBER 2018 INTERIM GUIDELINES HIV TREATMENTUPDATED (...) RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV: INTERIM GUIDELINES SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION DECEMBER 2018WHO/CDS/HIV/18.51 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https

2019 World Health Organisation HIV Guidelines

43. Canadian HIV Pregnancy Planning Guidelines

Canadian HIV Pregnancy Planning Guidelines No. 354-Canadian HIV Pregnancy Planning Guidelines - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 40, Issue 1, Pages 94–114 No. 354-Canadian HIV Pregnancy Planning Guidelines x Mona Loutfy , MD, MPH (Principal Author) Toronto, ON x V. Logan Kennedy , RN (Principal Author) Toronto, ON x Vanessa Poliquin , MD (Principal Author) Winnipeg, MB x Frederick Dzineku , MD (Principal (...) and Gynaecology, St. Michael's Hospital, Toronto, ON. , MD (Principal Author)* , x Mark H. Yudin Correspondence Corresponding Author: Dr. Mark Yudin, Department of Obstetrics and Gynaecology, St. Michael's Hospital, Toronto, ON. Toronto, ON No. 354, January 2018 (Replaces No. 278, June 2012) DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Abstract Objective The objective of the Canadian HIV Pregnancy Planning Guidelines is to provide clinical

2018 Society of Obstetricians and Gynaecologists of Canada

44. HIV

HIV Top results for hiv - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading (...) history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hiv The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest

2018 Trip Latest and Greatest

45. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life ABamford,*ATurkova,*HLyall, CFoster, NKlein, DBastiaans, DBurger, SBernardi, KButler, EChiappini, 1 2 3 3 4 5 5 6 7 8 P Clayden, 9 M Della Negra, 10 V Giacomet, 11 C (...) Institute of Child Health, University College London, London, UK, 5 Radboud University Medical Center, Nijmegan, The Netherlands, 6 University Department of Immunology and Infectious Disease, Bambino Gesù Children’s Hospital, Rome, Italy, 7 Our Lady’s Children’s Hospital Crumlin & University College Dublin, Dublin, Ireland, 8 Meyer University Hospital, Florence University, Florence, Italy, 9 HIV i-Base, London, UK, 10 Emilio Ribas Institute of Infectious Diseases, Sao Paulo, Brazil, 11 Paediatric

2018 The Children's HIV Association

46. Preparing HIV-infected children and adolescents for travel

course of standby treatment is warranted. In addition TD prophylaxis is offered to selected travellers who are at risk of TD because of their medication or pre-existing morbidity. This includes those who require stable absorption of medications, and HIV positive children on ART may fit this category. For standby treatment or prophylaxis the antibiotic choice should cover E. Coli/ ETEC/ Salmonella/ Shigella and Campylobacter species. Co-trimoxazole can reduce TD risk and it is preferred prophylactic (...) , but will not require RIG. Choice of vaccine and schedule Approximately 95% of HIV negative adults will respond to a full course of rabies pre exposure vaccine, and the antibodies are long lived. In HIV positive adults a reduced response to vaccination occurs, particularly in those with lower CD4 counts, and there is no data for HIV positive children. If HIV positive children receive this vaccine as pre-exposure prophylaxis antibody titres could be checked 2 weeks after the last vaccine dose and those with titres

2018 The Children's HIV Association

47. Maintaining and improving quality of care within HIV clinical services

, race, ethnicity, geographical location, religion, socioeconomic status or linguistic or political affiliation; • integrated: providing care that is coordinated across levels and providers and makes available the full range of health services throughout the life-course; and • efficient: maximizing the benefit of available resources and avoiding waste. Source: Why quality universal health coverage? (8).Maintaining and improving quality of care within HIV clinical services, 2019 6 QUALITY MANAGEMENT (...) Maintaining and improving quality of care within HIV clinical services MAINTAINING AND IMPROVING QUALITY OF CARE WITHIN HIV CLINICAL SERVICES JULY 2019 TECHNICAL BRIEF HIV TREATMENT WHO/CDS/HIV/19.17 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/ licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute

2019 World Health Organisation HIV Guidelines

48. Canadian HIV Pregnancy Planning Guidelines

Canadian HIV Pregnancy Planning Guidelines No. 354-Canadian HIV Pregnancy Planning Guidelines - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 40, Issue 1, Pages 94–114 No. 354-Canadian HIV Pregnancy Planning Guidelines x Mona Loutfy , MD, MPH (Principal Author) Toronto, ON x V. Logan Kennedy , RN (Principal Author) Toronto, ON x Vanessa Poliquin , MD (Principal Author) Winnipeg, MB x Frederick Dzineku , MD (Principal (...) and Gynaecology, St. Michael's Hospital, Toronto, ON. , MD (Principal Author)* , x Mark H. Yudin Correspondence Corresponding Author: Dr. Mark Yudin, Department of Obstetrics and Gynaecology, St. Michael's Hospital, Toronto, ON. Toronto, ON No. 354, January 2018 (Replaces No. 278, June 2012) DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Abstract Objective The objective of the Canadian HIV Pregnancy Planning Guidelines is to provide clinical

2018 Society of Obstetricians and Gynaecologists of Canada

49. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis

British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019) Guideline Development Group: Cara Saxon (Lead Author), Anne Edwards, Riina Rautemaa- Richardson, Caroline Owen, Bavithra Nathan, Bret Palmer, Clare Wood, Humera Ahmed, Sameena Ahmad, Patient Representatives, Mark FitzGerald (CEG Editor) Clinical Effectiveness Group (...) (CEG), British Association for Sexual Health and HIV (BASHH) NEW IN THE 2019 GUIDELINES Terminology: • The new guidelines refer to ‘acute’ and ‘recurrent’ vulvovaginal candidiasis (VVC) and no longer use the terms ‘uncomplicated’ and ‘complicated’ VVC; the new definitions are felt to be more reflective of how women with VVC typically present to clinical services and are subsequently managed • The elements of complicated VVC where single dose treatments are not always appropriate are still covered

2019 British Association for Sexual Health and HIV

50. Vaccination of HIV infected children

on immunisation can be found: - “Guidance on vaccination of HIV-infected children in Europe”. Paediatric European Network for Treatment of AIDS (PENTA) Vaccines Group. HIV Med. 2012. - Immunisation against infectious diseases GOV.UK, The Green Book. Routine Childhood Immunisations, Autumn 2018. Table 2. Indicators of severe immunosupression (CDC, 1994) Age CD4 count CD4% 100 IU/L. If 10 but <100 IU/L after primary course, offer one booster vaccine and recheck serology after 6-8 weeks) Notes. 1. If boosters (...) Vaccination of HIV infected children Vaccination of HIV infected children (UK schedule, 2018) Abbreviation list DTaP/IPV/Hib – diphtheria/tetanus/acellular pertussis/inactivated polio vaccine/ Haemophilus influenzae type b DTaP/IPV or dTaP/IPV - diphtheria/tetanus/acellular pertussis/inactivated polio vaccine “D” - vaccines containing the higher dose of diphtheria toxoid (contain not less than 30IU) “d” - vaccines containing the lower dose of diphtheria toxoid (contain approximately 2IU) PCV13

2018 The Children's HIV Association

51. Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV

to uncertainty in the parameters. PrEP effectiveness was the main driver of cost-effectiveness in the model. ? The mean number of people expected to join the programme in year one is 1,705 people (95% CI: 617 to 3,452) based on model calibration to the observed number who enrolled in Scotland’s national programme. On average, 173 HIV infections are estimated to be averted over the course of the first five years in the base case analysis. ? In the first year, PrEP medications alone are estimated to cost €1.1m (...) Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV 14 June 2019 Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV Health Information and Quality Authority Page 2 of 257 Health technology assessment of a PrEP programme for populations at substantial risk

2019 Health Information and Quality Authority

52. Bictegravir / emtricitabine / tenofovir alafenamide / fumarate (Biktarvy) - HIV Infections

exposure is low; estimates are on the order of 0.1% per contact for heterosexual transmission, but this varies considerably and increases with concurrent ulcerative STDs, high HIV viral load in the subject, and lack of antiretroviral therapy. 2.1.2. Epidemiology There are approximately 37 million people worldwide living with HIV-1. HIV-1 infection remains a life- threatening disease in infected persons who do not receive adequate treatment sufficiently early in the course of the infection (...) Bictegravir / emtricitabine / tenofovir alafenamide / fumarate (Biktarvy) - HIV Infections 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 26 April 2018 EMA/293559/2018 Committee for Medicinal Products for Human Use (CHMP

2018 European Medicines Agency - EPARs

53. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis E1448 CMAJ | NOVEMBER 27, 2017 | VOLUME 189 | ISSUE 47 © 2017 Joule Inc. or its licensors N ew HIV infections occur every year in Canada, 1 highlighting the need for integrated prevention programs. Pre-exposure pro- phylaxis (PrEP) and nonoccupational postexposure prophy- laxis (nPEP) are two important strategies for preventing HIV that should be considered standard of care and implemented (...) as components of a comprehensive response to the epidemic. Pre-exposure prophylaxis is the use of certain antiretroviral medications by HIV-uninfected per- sons who are at high, ongoing risk of HIV acquisition, beginning before and continuing after potential HIV exposures. Postexposure prophy- laxis (PEP) involves 28 days of antiretroviral medications immediately after a specific HIV exposure, and is “nonoccupational” (nPEP) when used after sexual and injection drug use exposures, rather than acci- dental

2017 CPG Infobase

54. Knowledge of HIV and Related Best Practices Among Non-HIV Specific Health Care Providers

testing as a regular screening test for all patients (11). The authors of the U.S. study comparing generalist, “expert generalist” and infectious disease specialists stressed that generalists can be trained to provide high-quality care to patients with complex chronic illness through multiple means, including continuing education courses, conferences and literature updates (9). Similarly, a study of pre-exposure prophylaxis (PrEP) knowledge among HIV-providers and non-HIV- providers in California (...) Knowledge of HIV and Related Best Practices Among Non-HIV Specific Health Care Providers RAPID RESPONSE SERVICE | #98, OCTOBER 2015 1 RAPID RESPONSE SERVICE THE ONTARIO HIV TREATMENT NETWORK References 1. Rosen NO, Knauper B, Mozessohn L, Ho MH. Factors affecting knowledge of sexually transmitted infection transmis- sibility in healthcare providers: Results from a national survey. Sexually Trans- mitted Diseases 2005;32(10):619-24. 2. Farley JE, Hayat MJ, Murphy J, Sheridan-Malone E, Anderson J

2015 Ontario HIV Treatment Network

55. HIV after 40 in rural South Africa: A life course approach to HIV vulnerability among middle aged and older adults. (PubMed)

HIV after 40 in rural South Africa: A life course approach to HIV vulnerability among middle aged and older adults. South Africa has the highest number of people living with HIV in the world (over 6 million) as well as a rapidly aging population, with 15% of the population aged 50 and over. High HIV prevalence in rural former apartheid homeland areas suggests substantial aging with HIV and acquisition of HIV at older ages. We develop a life course approach to HIV vulnerability, highlighting (...) the rise and fall of risk and protection as people age, as well as the role of contextual density in shaping HIV vulnerability. Using this approach, we draw on an innovative multi-method data set collected within the Agincourt Health and Demographic Surveillance System in South Africa, combining survey data with 60 nested life history interviews and 9 community focus group interviews. We examine HIV risk and protective factors among adults aged 40-80, as well as how and why these factors vary among

Full Text available with Trip Pro

2015 Social Science & Medicine

56. CHIVA Guidance on Transition for adolescents living with HIV

2016. Available from: http://www.chipscohort.ac.uk/summary_data.asp [Accessed 31.12.2016]. 4. Collins IJ, Foster C, Tostein A, Tookey P, Riordan A, Dunn D, Gibb DM, Judd A. Clinical status of adolescents with perinatal HIV at transfer to adult care in the UK/Ireland. CID in press 2016. 5. Ferrand RA, Corbett EL, Wood R et al. AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 2009; 23(15): 2039-46. 6. Judd A, Ferrand R (...) CHIVA Guidance on Transition for adolescents living with HIV 1 CHIVA Guidance on Transition for adolescents living with HIV Authors: Caroline Foster Date of preparation: September 2010 Date reviewed: February 2017 Next review date: February 2019 This document replaces 2 previous CHIVA documents: “Guidance on transition and long term follow up services for adolescents with HIV infection acquired in infancy”, Melvin et al 2005. “Growing up, Gaining independence: Principles for transitional care

2017 The Children's HIV Association

57. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

-risk sexual behaviours individuals who use stimulant drugs associated with high-risk behaviours, such as methamphetamine individuals diagnosed with at least one anogenital STI in the last year individuals who have been prescribed non-occupational post-exposure prophylaxis (nPEP) who demonstrate continued high-risk behaviour or have used multiple courses of nPEP In summary, there is no single program or set of criteria for providing HIV PrEP in the US. All US programs identified in this report (...) continued high‑risk behaviour or have used multiple courses of nPEP England (draft) 40 Individuals considered to be at substantial risk of HIV acquisition include those who are: MSMs or transgender persons who are currently HIV-negative and who are clinically assessed to be at high risk of HIV acquisition through fulfilling the following criteria: have a documented confirmed HIV-negative test during an earlier episode of care in the preceding year (i.e., 42 days to 365 days ago) report condomless

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

58. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

-risk sexual behaviours individuals who use stimulant drugs associated with high-risk behaviours, such as methamphetamine individuals diagnosed with at least one anogenital STI in the last year individuals who have been prescribed non-occupational post-exposure prophylaxis (nPEP) who demonstrate continued high-risk behaviour or have used multiple courses of nPEP In summary, there is no single program or set of criteria for providing HIV PrEP in the US. All US programs identified in this report (...) continued high‑risk behaviour or have used multiple courses of nPEP England (draft) 40 Individuals considered to be at substantial risk of HIV acquisition include those who are: MSMs or transgender persons who are currently HIV-negative and who are clinically assessed to be at high risk of HIV acquisition through fulfilling the following criteria: have a documented confirmed HIV-negative test during an earlier episode of care in the preceding year (i.e., 42 days to 365 days ago) report condomless

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

59. HIV PrEP

, such as methamphetamine individuals diagnosed with at least one anogenital STI in the last year individuals who have been prescribed non-occupational post-exposure prophylaxis (nPEP) who demonstrate continued high-risk behaviour or have used multiple courses of nPEP In summary, there is no single program or set of criteria for providing HIV PrEP in the US. All US programs identified in this report mention serodiscordant couples, MSMs, transgender individuals, sex workers and injection drug users as eligible HIV PrEP (...) HIV PrEP HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies | CADTH.ca CADTH Document Viewer HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies Table of Contents Search this document HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies August 2017 Context Infection with the HIV continues

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

60. Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA ? addressing the vulnerable populations

Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA ? addressing the vulnerable populations SCIENTIFIC ADVICE Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA – addressing the vulnerable populations www.ecdc.europa.euECDC SCIENTIFIC ADVICE Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA – addressing the vulnerable populations ii This report (...) was commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Otilia Mårdh and Tarik Derrough, with additional input from Andrew Amato-Gauci and Helena de Carvahlo- Gomes. It was written by Carita Savolainen-Kopra, Mia Kontio, Jukka Lindeman, Jaana Isojärvi, Kirsi Liitsola and Marjukka Mäkelä from THL Finland and revised by ECDC. This guidance draws on several literature reviews and a survey entitled ‘Antenatal screening for HIV, hepatitis B, syphilis and rubella

2017 European Centre for Disease Prevention and Control - Public Health Guidance

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>